Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jun Liu, M.D.


Williams College, MA, USABA06/2010Biology
University of Cambridge, Cambridge, UKPhD08/2015Physiology, development, and neuroscience
Harvard Medical School, Boston, MAMD05/2020Medicine
2010 - 2014
Dr. Herschel Smith Fellowship
2017 - 2020
HMS ”Agents of Change” challenge grant
2015 - 2016
Ambassador Milton A. & Roslyn Wolf Scholarship
2015 - 2020
Elene and Alan C. Yeung, MD ’84 Scholarship
2018 - 2019
Scholar in medicine research fellowship

Available: 11/22/22, Expires: 11/19/24

Hypomethylating agent (HMA) drugs are widely used to treat patients with myelodysplastic syndromes (MDS), a type of bone marrow failure and pre-leukemic disorder, around the world, but only about half of the MDS patients respond to HMA treatment. The survival of MDS patients after HMA failure is less than 6 months, many of whom transform to acute leukemia. Based on our study published in New England Journal of Medicine in 2022, we propose that HMA treatment leads to upregulation of the oncogene SALL4, which is the basis for the poor clinical outcome and offers a novel target for designing precision medicine. SALL4 is an oncofetal protein. While loss-of-function studies demonstrate that SALL4 is essential for cancer cell survival, gain-of-function studies demonstrate that induced expression in SALL4 negative cancer cells leads to drug resistance and metastasis. Notably, transgenic SALL4 mice develop MDS and acute myeloid leukemia (AML). Although our data showed that MDS patients on HMA monotherapy with SALL4 upregulation have a poor prognosis, we also demonstrated that upregulation of SALL4 renders the cancer cells dependent on (or “addicted to”) SALL4, and thus more vulnerable to additional, targeted therapy. To better help MDS patients, we propose to develop a SALL4-centerned diagnostic assay (biomarker development, and validation via a prospective clinical cohort), and conduct mechanistic studies on the poor prognosis mediated by elevated SALL4. In addition, we propose to test SALL4-based therapies in cell and animal models. Overall, by completing our proposed studies, we can delineate the mechanism and impact of upregulation of SALL4 by HMA therapy in MDS patients. More importantly, we can provide proof-of-concept, pre-clinical studies on a SALL4-centered therapy based on its known function(s) and mechanism(s) in MDS/AML. In the near future, we plan to translate the knowledge we will gain from these studies into clinical personalized management of MDS patients on HMA therapy. Student will work closely with oncology and transfusion medicine mentors, and can participate in biomarker development and validations, and/or SALL4 targeting drug development. Chai lab: https://chailab.bwh.harvard.edu/ NEJM paper:https://www.nejm.org/doi/full/10.1056/NEJMoa2119771 Contact: Jun Liu (HMS class of 2020, Clinical Fellow at Harvard Medical School, Transfusion Medicine fellow 2023-2024), jliu71@bwh.harvard.edu

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Liu's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (67)
Co-Authors (9)
Similar People (60)
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.